EA035959B1 - Последовательность модифицированного эндолизина kz144 - Google Patents

Последовательность модифицированного эндолизина kz144 Download PDF

Info

Publication number
EA035959B1
EA035959B1 EA201691004A EA201691004A EA035959B1 EA 035959 B1 EA035959 B1 EA 035959B1 EA 201691004 A EA201691004 A EA 201691004A EA 201691004 A EA201691004 A EA 201691004A EA 035959 B1 EA035959 B1 EA 035959B1
Authority
EA
Eurasian Patent Office
Prior art keywords
leu
lys
thr
ala
gly
Prior art date
Application number
EA201691004A
Other languages
English (en)
Russian (ru)
Other versions
EA201691004A1 (ru
Inventor
Стефан Миллер
Рейнхард Стернер
Хейке Стуер
Original Assignee
Лисандо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лисандо Аг filed Critical Лисандо Аг
Publication of EA201691004A1 publication Critical patent/EA201691004A1/ru
Publication of EA035959B1 publication Critical patent/EA035959B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201691004A 2013-11-14 2014-11-14 Последовательность модифицированного эндолизина kz144 EA035959B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/073869 WO2015070911A1 (en) 2013-11-14 2013-11-14 Modified kz144 endolysin sequence
PCT/EP2014/074671 WO2015071436A1 (en) 2013-11-14 2014-11-14 Modified kz144 endolysin sequence

Publications (2)

Publication Number Publication Date
EA201691004A1 EA201691004A1 (ru) 2017-01-30
EA035959B1 true EA035959B1 (ru) 2020-09-07

Family

ID=49582760

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691004A EA035959B1 (ru) 2013-11-14 2014-11-14 Последовательность модифицированного эндолизина kz144

Country Status (10)

Country Link
US (1) US10184120B2 (https=)
JP (1) JP6745720B2 (https=)
KR (1) KR102302044B1 (https=)
CN (1) CN105793419B (https=)
AU (1) AU2014350104B2 (https=)
BR (1) BR112016011091B1 (https=)
CA (1) CA2929686C (https=)
EA (1) EA035959B1 (https=)
MX (1) MX374403B (https=)
WO (2) WO2015070911A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4115897A1 (en) 2015-09-17 2023-01-11 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
CA3022334A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
WO2017203471A1 (en) * 2016-05-27 2017-11-30 Sasinapas Co., Ltd. Endolysin variant
WO2018100408A1 (en) * 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
MX2019011808A (es) * 2017-04-03 2020-01-09 Sasinapas Co Ltd Endolisinas de gram-negativas modificadas.
WO2019229184A1 (en) * 2018-05-30 2019-12-05 Lysando Ag Novel antimicrobial fusion proteins
CN111304181B (zh) * 2020-02-17 2021-11-23 华东理工大学 一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用
KR20250044545A (ko) 2023-09-23 2025-04-01 조배근 사료급이기 청소기

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149792A2 (en) * 2009-06-26 2010-12-29 Katholieke Universiteit Leuven, K.U. Leuven R&D Antimicrobial agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289092C (en) * 1987-01-15 1991-09-17 Novartis Vaccines And Diagnostics, Inc. Thermostable human cu/zn superoxide dismutase muteins
EP0285123A3 (en) * 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
ZA936811B (en) * 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
JPH08127540A (ja) * 1994-09-09 1996-05-21 Takeda Chem Ind Ltd 抗潰瘍医薬
WO2009024327A2 (en) * 2007-08-22 2009-02-26 Profos Ag New proteins for use in human and animal staphylococcus infections
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
AU2010264659B2 (en) 2009-06-26 2016-08-04 Lysando Aktiengesellschaft Antimicrobial agents
KR20120059576A (ko) * 2009-08-24 2012-06-08 뤼산도 홀딩 아게 신규한 엔도리신 OBPgpLYS
SG184836A1 (en) * 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
KR20130142837A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 슈도모나스 에루기노사의 박테리오파아지 및 그 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149792A2 (en) * 2009-06-26 2010-12-29 Katholieke Universiteit Leuven, K.U. Leuven R&D Antimicrobial agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. FOKINE, K. A. MIROSHNIKOV, M. M. SHNEIDER, V. V. MESYANZHINOV, M. G. ROSSMANN: "Structure of the Bacteriophage �KZ Lytic Transglycosylase gp144", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 283, no. 11, 14 March 2008 (2008-03-14), pages 7242 - 7250, XP055130395, ISSN: 00219258, DOI: 10.1074/jbc.M709398200 *
BRIERS, Y. ; SCHMELCHER, M. ; LOESSNER, M.J. ; HENDRIX, J. ; ENGELBORGHS, Y. ; VOLCKAERT, G. ; LAVIGNE, R.: "The high-affinity peptidoglycan binding domain of Pseudomonas phage endolysin KZ144", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 383, no. 2, 29 May 2009 (2009-05-29), AMSTERDAM, NL, pages 187 - 191, XP026057388, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2009.03.161 *
LOPEZ, R. GARCIA, E. GARCIA, P.: "Enzymes for anti-infective therapy: phage lysins", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, ELSEVIER, AMSTERDAM, NL, vol. 1, no. 4, 1 December 2004 (2004-12-01), AMSTERDAM, NL, pages 469 - 474, XP004694307, ISSN: 1740-6773, DOI: 10.1016/j.ddstr.2004.09.002 *
YVES BRIERS, GUIDO BRIERS, ANNELEEN VOLCKAERT, STIJN CORNELISSEN, CHRIS LAGAERT, KIRSTEN MICHIELS, ROB HERTVELDT, LAVIGNE: "Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages ?KZ and EL", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENCE, vol. 65, no. 5, 1 September 2007 (2007-09-01), pages 1334 - 1344, XP055119325, ISSN: 0950382X, DOI: 10.1111/j.1365-2958.2007.05870.x *

Also Published As

Publication number Publication date
KR20160085342A (ko) 2016-07-15
WO2015071436A1 (en) 2015-05-21
JP2016537979A (ja) 2016-12-08
KR102302044B1 (ko) 2021-09-15
US20160281074A1 (en) 2016-09-29
CN105793419A (zh) 2016-07-20
EA201691004A1 (ru) 2017-01-30
US10184120B2 (en) 2019-01-22
MX374403B (es) 2025-03-06
BR112016011091A2 (pt) 2017-12-05
CA2929686A1 (en) 2015-05-21
AU2014350104B2 (en) 2020-03-05
CN105793419B (zh) 2021-06-01
WO2015070911A1 (en) 2015-05-21
BR112016011091B1 (pt) 2024-02-06
CA2929686C (en) 2023-08-08
MX2016006277A (es) 2017-01-05
JP6745720B2 (ja) 2020-08-26
AU2014350104A1 (en) 2016-05-12
NZ719338A (en) 2022-03-25

Similar Documents

Publication Publication Date Title
EA035959B1 (ru) Последовательность модифицированного эндолизина kz144
Sitaram et al. Host-defense antimicrobial peptides: importance of structure for activity
US10167462B2 (en) Modified EL188 endolysin sequence
Nishimiya et al. Co‐operative effect of the isoforms of type III antifreeze protein expressed in Notched‐fin eelpout, Zoarces elongatus Kner
Scocchi et al. Structural aspects and biological properties of the cathelicidin PMAP‐36
JP6914321B2 (ja) カブトガニb因子改変体
CN109072211B (zh) 抗沙门氏菌的抗菌剂
US9434765B2 (en) High affinity SUMO traps
Wang et al. Rapid and efficient production of cecropin A antibacterial peptide in Escherichia coli by fusion with a self-aggregating protein
Login et al. A 20‐residue peptide of the inner membrane protein OutC mediates interaction with two distinct sites of the outer membrane secretin OutD and is essential for the functional type II secretion system in Erwinia chrysanthemi
Wicker-Planquart et al. Interactions of an essential Bacillus subtilis GTPase, YsxC, with ribosomes
Maier et al. Dynamitin mutagenesis reveals protein–protein interactions important for dynactin structure
EP3068877B1 (en) Modified kz144 endolysin sequence
Yin et al. The N-terminal coiled-coil domain of Arabidopsis CROWDED NUCLEI 1 is required for nuclear morphology maintenance
HK1228944A1 (en) Modified kz144 endolysin sequence
HK1228944B (en) Modified kz144 endolysin sequence
EP3068878B1 (en) Modified el188 endolysin sequence
NZ719338B2 (en) Modified kz144 endolysin sequence
Xi et al. The minimal α‐crystallin domain of Mj Hsp16. 5 is functional at non‐heat‐shock conditions
Baliova et al. Comparison of SynCAM1/CADM1 PDZ interactions with MUPP1 using mammalian and bacterial pull‐down systems
Dhar Outer Membrane Protein Evolution: Past, Present, and Future
Ozawa et al. Thermal stability of the synthetic peptides with the sequence of fish fast skeletal muscle tropomyosin
Perumal The role of Tyr540 in dimerisation of the FOXP forkhead domain
Liu Characterization of two AAA+ proteins: Escherichia coli ClpB and human torsinA
Burr Characterisation of the conserved protein IMPACT from yeast (Yih1): a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University, Manawatu, New Zealand

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM